Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9453953 | 0.90 | RAB9A (0.66) | ALDH1A1SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL5445603 | 0.82 | SMN1; SMN2 (0.73) | ALDH1A1SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL456128 | 0.82 | MAPT (0.59) | ALDH1A1SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL14386215 | 0.82 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL19851224 | 0.82 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL17637677 | 0.82 | TAAR1 (0.62) | ALDH1A1SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL19851219 | 0.81 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL8867893 | 0.81 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2MAPTHPGDCYP1A2 | |
| SCHEMBL17637653 | 0.81 | RAB9A (0.57) | ALDH1A1SMN1; SMN2RAB9APOLBMAPT | |
| SCHEMBL19851240 | 0.79 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2RAB9APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023288015-A1 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20160022842-A1 | FORMATION AND USES OF EUROPIUM | WAYNE STATE UNIVERSITY (US) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022842-A1 | FORMATION AND USES OF EUROPIUM | LETM1, CECR2, MCU | ALDH1A1 4648/4885SMN1; SMN2 2447/4885RAB9A 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.